Home > News > Nanotech Disappoints in Europe
July 6th, 2007
Nanotech Disappoints in Europe
Anxious investors are but one of the problems plaguing nanotechnology, the cutting-edge science of manipulating materials and microscopic devices at the atomic level.
Consider the story of Oxonica, Britain's highest-profile publicly traded nanotech startup. It revealed in late April that one of its key products—a catalyst designed to cut vehicle emissions when combined with high-sulfur diesel fuel—didn't work as expected, leading to the cancellation of a big supply deal with Turkish oil retailer Petrol Ofisi.
Oxonica shares were suspended until June, but when trading began again, the price plunged nearly 75%, wiping out $80.7 million in Oxonica's market capitalization. To save face, the company noted that Petrol Ofisi had agreed to work with it on another project involving low-sulfur diesel. But the damage was done, and Oxonica's share price is still only half what it was in April.
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013
Iran to Hold Int'l Forum on Nanotechnology Economy (IFNE2013) May 30th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Working backward: Computer-aided design of zeolite templates: Rice scientists apply drug-design lessons to production of industrial minerals June 17th, 2013
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013